Biovail Sues FDA Over Generic Wellbutrin

Law360, New York (December 19, 2006, 12:00 AM EST) -- Scrambling to halt shipments of a generic copy of the antidepressant Wellbutrin XL, Canadian pharmaceutical company Biovail Corp. has renewed its fight against the U.S. Food and Drug Administration in another lawsuit.

Last week, the FDA cleared the way for Impax Laboratories Inc. to start selling its generic version of the drug. In a last-ditch effort, Biovail filed suit in the U.S. District Court for the District of Maryland on Monday, seeking an order rescinding FDA approval and putting a stop to shipments of the generic...
To view the full article, register now.